GCLC and schizophrenia: Glutathione has been found to be reduced (−27%) in the CSF from drug-naïve patients with schizophrenia, in postmortem studies (−41%) of patients with schizophrenia vs. normal control subjects, and polymorphisms in the genes for key components of glutathione generation [glutamate cysteine ligase modifier subunit (gclm) and the catalytic subunit for glutamate cysteinen ligase (gclc)] are linked to the risk for schizophrenia.